{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-005225","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.861855+00:00","generated_at":"2026-06-11T20:58:30.737973+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Aptose Q2 net loss $14.1M; TUS/VEN doublet 50% CRc; Hanmi commits up to $7M","bullets":["TUS/VEN doublet: 50% CRc (5/10 evaluable); 44% CRc in prior-venetoclax failures (4/9); 43% in FLT3-WT (3/7).","Hanmi Pharma commits up to $7M or 19.99% ownership in two tranches; first $3M by Aug-end conditional on TSX listing.","Q2 net loss $14.1M vs $10.6M prior year; cash $23.3M at June 30, expected to fund operations through March 2024.","FDA End of Phase 1 meeting completed; monotherapy RP2D of 80 mg daily confirmed; accelerated path remains open."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-005225","json":"https://secwatch.observer/filing/0001171843-23-005225.json","markdown":"https://secwatch.observer/filing/0001171843-23-005225.md","text":"https://secwatch.observer/filing/0001171843-23-005225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184323005225/0001171843-23-005225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184323005225/f8k_081023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T20:58:30.737973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fe03d6d3629a52c4f5bb18c3e2c37364d1ced6ad","claim":"Aptose Biosciences Inc. reported three months ended June 30, 2023 results: net income $(14,129 ) thousand, EPS $(2.27 ) per share.","evidence_excerpt":"Aptose Reports Results for the Second Quarter 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184323005225/0001171843-23-005225-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended June 30, 2023"},{"label":"Net income","value":"$(14,129 ) thousand"},{"label":"EPS","value":"$(2.27 ) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}